Op2Lysis SAS announced the signature of a license agreement with CARLINA Technologies for exploiting its PEPTIDOTSTM technology.
Read the press release below for more information
Receipt of a decision to grant a patent from the European Patent Office for a strategic patent application related to Op2Lysis O2L-001 program for hemorrhagic stroke patients.
See the press release below
Op2Lysis receives the seal of Excellence for the development the first medical treatment dedicated to patients with intracerebral hemorrhage (EIC Accelerator – SME Phase II).
Op2Lysis project was scored as a high quality proposal in this highly competitive evaluation process. #SMEinstrument #SealOfExcellence
More Information about SME instrument: https://ec.europa.eu/programmes/horizon2020/en/h2020-section/eic-accelerator-pilot
Op2Lysis has obtained the Innovative Young Company label from the French Ministry of Higher Education and Research. Together with CIFRE contract, this label is the second key support received by Op2Lysis over these last few weeks to strengthen its innovation.
Op2Lysis has been ranked as the 7th best start up (out of the initially 100 companies selected at the beginning of the competition) at the Big Booster Demo Days 2018, in Lyon (France) and is now a member of the 2018 Big Booster Class. This success offers the opportunity to fly to Boston and to Shanghai in the next few months in order to consolidate existing partnerships and to open new opportunities for business with the USA and China.
More information on Big Booster: http://www.bigbooster.org/index.php